1 Department of Reproductive Medicine and Surgery, Government Medical College, Thiruvananthapuram, Kerala, India.
2 Department of Rheumatology, SUM Ultimate Medicare, Bhubaneswar, Odisha, India.
World Journal of Advanced Research and Reviews, 2025, 25(02), 2693-2696
Article DOI: 10.30574/wjarr.2025.25.2.0542
Received on 08 January 2025; revised on 22 February 2025; accepted on 25 February 2025
We present a case of oligohydramnios induced by NSAID use (Etoricoxib and Diclofenac) in the second trimester. A 20-year-old primigravidae with an uncomplicated early trimester, was advised at 21 weeks to take Etoricoxib for five days due to knee bursitis after which she self-medicated with Diclofenac for a week. Due to complaints of reduced fetal movement, a scan was done at 23 weeks which revealed reduced liquor status. She was advised against NSAID use and followed up with a scan three weeks later which showed a reversal of oligohydramnios. While NSAIDs are discouraged in the third trimester, limited awareness exists regarding second-trimester risks, especially with self-medication. But our case emphasizes the need for strict monitoring while using NSAIDs even during the second trimester of pregnancy. This case is one of the earliest documented cases involving the adverse effect of Etoricoxib, a selective COX-2 inhibitor, on pregnancy and further study is required to look for long-term effects.
NSAIDs; Oligohydramnios; Etoricoxib; Second Trimester; COX2 inhibitor
Preview Article PDF
Sholen Acharya and Deepak Rath. Non-steroidal anti-inflammatory drugs induced oligohydramnios in second trimester pregnancy: A case report. World Journal of Advanced Research and Reviews, 2025, 25(02), 2693-2696. Article DOI: https://doi.org/10.30574/wjarr.2025.25.2.0542.
Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0